There remains a great unmet need for new effective and safe treatments for SLE. We have participated in a number of investigations of studies from preclinical, phase 1, 2 and 3 for three separate molecules designed to treat SLE. The search for more effective therapies for SLE continues.

  • Resolve – 132 MD Phase 0/1 study.  Clinical correlation of U1 RNA and Y1 RNA gene signatures in patients with Systemic Lupus Erythematosis.  (Resolve Therapeutics).
  • Resolve-132 MD Phase 1 study. Safety and Biologic effects of anti RNA Immune Complex Monoclonal antibody on U1 RNA and Y1 RNA gene signatures in patients with Systemic Lupus Erythematosis. (Resolve Therapeutics).
  •  Pharmacokinetic Evaluation of Tabatumab Following Subcutaneous Administration in Systemic Lupus. Protocol H9B-MC-BCEI. (Eli Lilly).
  • A Phase III Multi-center Randomized, Double-blind, Placebo-controlled, 52-Week Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients with Systemic Lupus Erythematosus. (Eli Lilly).
  • TULIP (Treatment of Uncontrolled Lupus via the Interferon Pathway) study that evaluated the effectiveness and safety of anifrolumab versus placebo in patients with moderately to severely active, autoantibody-positive SLE (AstraZeneca).